
Join to view full profile
400 Parnassus AveSan Francisco, CA 94143
Phone+1 415-353-2421
Fax+1 415-353-2467
Dr. Martin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1993 - 1996
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1989 - 1992
Uconn School Of MedicineClass of 1989
Certifications & Licensure
CA State Medical License 1991 - 2028
TX State Medical License 1999 - 2002
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Brian Durie Award International Myelona Foundation, 2023
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
- Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Publications & Presentations
PubMed
- Managing Novel CAR T-Cell Toxicities in Multiple Myeloma.Kwan-Keat Ang, Jodi Lipof, Anupama Kumar, Lekha Mikkilineni, Alfred Chung
Cancer Journal. 2026-09-25 - 3 citationsIsatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma: dynamics of MRD negativity in the IMROZ study.Robert Z Orlowski, Meletios A Dimopoulos, Xavier Leleu, Thierry Facon, Tadao Ishida
Blood. 2026-06-04 - Plain language summary of publication of how long people with relapsed multiple myeloma lived after treatment in the IKEMA study: Isatuximab plus carfilzomib and dexam...Kwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Marcelo Capra
Future Oncology. 2026-06-01
Press Mentions
FDA Approves New CAR T Cancer Therapy for Form of Multiple MyelomaFebruary 28th, 2022
New Data from CARTITUDE-1 Study Show Continued Deep and Durable Responses of Ciltacabtagene Autoleucel (Cilta-Cel) in Treatment of Heavily Pre-Treated Patients with Multiple MyelomaDecember 12th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: